Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Australian Government, the most common co-covered peer. Briumvi (ublituximab) appears in 1 tracked Biotech story from July 15, 2026. The tracked stories average 11 original sources each.
Last mentioned: Jul 15, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Australian Government, the most common co-covered peer. Briumvi (ublituximab) appears in 1 tracked Biotech story from July 15, 2026. The tracked stories average 11 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Briumvi (ublituximab). Shared-story counts are live from our verified record — not editorial picks.
A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Source: maitlandmercury.com.au · ulladullatimes.com.au
Briumvi (ublituximab) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
